May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Topical Cromolyn Inhibits the Growth of Human Choroidal Melanoma Xenografts
Author Affiliations & Notes
  • R. D. Braun
    Anatomy & Cell Biology, Wayne State Univ Sch of Med, Detroit, Michigan
    Karmanos Cancer Institute, Wayne State Univ Sch of Med, Michigan
  • K. S. Vistisen
    Anatomy & Cell Biology, Wayne State Univ Sch of Med, Detroit, Michigan
  • Footnotes
    Commercial Relationships  R.D. Braun, None; K.S. Vistisen, None.
  • Footnotes
    Support  NIH grants R03 EY016795 and P30 EY04068
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 62. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. D. Braun, K. S. Vistisen; Topical Cromolyn Inhibits the Growth of Human Choroidal Melanoma Xenografts. Invest. Ophthalmol. Vis. Sci. 2008;49(13):62. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Current treatments of primary choroidal melanoma can negatively affect patient vision, and new effective, vision-sparing therapies for choroidal melanomas are needed. Choroidal melanomas from patients strongly express S100A1, which is a member of the S100 family of calcium-binding proteins. S100A1, S100P, and other S100 proteins are known to interact with the receptor for advanced glycation end products (RAGE), resulting in an increase in cancer cell proliferation and survival. Recently, inhibition of RAGE activation by blocking S100P with the antiallergy drug cromolyn successfully inhibited the growth of human pancreatic tumor xenografts in scid mice. Cromolyn is commercially available for topical application to treat ocular itching. Since it has been shown to bind S100A1, we hypothesize that topical application of this drug could inhibit the growth of choroidal melanoma.

Methods: : Orthotopic xenografts were grown in 7 eyes by implanting human choroidal melanoma OCM-1 spheroids into the suprachoroidal space of nude, athymic WAG/Nij-rnu/rnu rats. Beginning the day after implantation, all rats received either single drops of 6% cromolyn or artificial tears twice daily (Monday-Friday) for the next 28 days. Four rats received cromolyn, and three rats served as controls and received artificial tears. On Days 7, 14, 21, and 28 after implantation, the rats were anesthetized with ketamine/xylazine, and high-frequency ultrasound was used to measure tumor volume.

Results: : OCM-1 spheroids and xenografts expressed high levels of S100A1. On Day 28, tumors in the cromolyn-treated rats were significantly smaller than those in the control rats, 7.9 ± 2.8 mm3 (mean ± SD, n=4) compared to 26.5 ± 8.8 mm3 (n=3), respectively (p=0.009, unpaired t-test).

Conclusions: : Topical application of cromolyn was effective at slowing the growth of primary human uveal melanomas when treatment began immediately after implantation. Whether cromolyn can inhibit growth of established tumors remains to be determined.

Keywords: melanoma • tumors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.